Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal dominant syndrome caused by pathogenic variants in the PTEN gene, characterized by hamartomas, overgrowth, neurodevelopmental disorders and an increased risk of various cancers, including breast, thyroid, and endometrial cancer. PHTS encompasses Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and Proteus-like syndrome.
PTEN function has not been fully characterized.
PTEN hamartoma tumor syndrome is associated with mutations in the PTEN gene.
Genetic testing for PTEN is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for PTEN hamartoma tumor syndrome has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
4 clinical trials registered, 2 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
99 publications have been identified in PubMed for PTEN hamartoma tumor syndrome. Research spans Review / Meta-Analysis (29%), Case Report / Case Series (27%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 29 |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 7:53 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about PTEN hamartoma tumor syndrome
Patient case studies | 27 | 27% |
Laboratory research | 16 | 16% |
Disease patterns and progression | 12 | 12% |
Clinical study results | 5 | 5% |
New treatment approaches | 4 | 4% |
Other research | 3 | 3% |
Testing and diagnosis research | 3 | 3% |
Krückel A (2026). [PMID: 41528496](https://pubmed.ncbi.nlm.nih.gov/41528496/). *Arch Gynecol Obstet*. [Review / Meta-Analysis]
Jonker R (2026). [PMID: 41825102](https://pubmed.ncbi.nlm.nih.gov/41825102/). *Eur J Paediatr Neurol*. [Epidemiology / Natural History]
Moreno Fernandes M (2026). [PMID: 41646565](https://pubmed.ncbi.nlm.nih.gov/41646565/). *Cureus*. [Case Report / Case Series]
Onur OE (2026). [PMID: 42049783](https://pubmed.ncbi.nlm.nih.gov/42049783/). *NPJ Genom Med*. [Basic Science / Preclinical]
Nazerani-Zemann T (2026). [PMID: 40938196](https://pubmed.ncbi.nlm.nih.gov/40938196/). *Clin Nucl Med*. [Case Report / Case Series]
Ródon J (2026). [PMID: 41475241](https://pubmed.ncbi.nlm.nih.gov/41475241/). *ESMO Open*. [Clinical Trial Publication]
Pálla S (2026). [PMID: 41165034](https://pubmed.ncbi.nlm.nih.gov/41165034/). *Int J Dermatol*. [Review / Meta-Analysis]
De Looze K (2026). [PMID: 41503170](https://pubmed.ncbi.nlm.nih.gov/41503170/). *ACG Case Rep J*. [Case Report / Case Series]
Mukhopadhyay A (2026). [PMID: 42112690](https://pubmed.ncbi.nlm.nih.gov/42112690/). *Orbit*. [Case Report / Case Series]
Riascos MC (2026). [PMID: 41483301](https://pubmed.ncbi.nlm.nih.gov/41483301/). *Virchows Arch*. [Review / Meta-Analysis]